LONDON, April 30, 2012 /PRNewswire/ -- Clarion Golf [http://www.clariongolf.co.uk ] and GameBook [http://www.golfgamebook.com ] today announced that Clarion Golf is offering

DALLAS, April 17, 2012 /PRNewswire/ -- Parks Associates today announced the

Join featured speaker Massimo Pezzini, VP & Gartner Fellow, Gartner, and Pradip Sitaram, Dell Boomi customer and SVP & CIO, Enterprise Business Partners LLC, to learn about iPaaS, its

A working group of the International Osteoporosis Foundation (IOF) has issued a literature review of prospective controlled studies comparing the efficacy and safety of two minimally invasive techniques for vertebral augmentation after spine fracture: vertebroplasty (VP) and balloon kyphoplasty (BKP).

EXTON, Pa., May 19, 2011 /PRNewswire/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced initiation of a Phase 2 dose-ranging clinical study to evaluate the safety, tolerability, and efficacy of VP 20621 for prevention of recurrence of Clostridium difficile infection (CDI) in adults previously treated for CDI. The objectives of this randomized, double-blind, placebo-controlled, dose ranging study are to evaluate the safety and tolerability of VP 20621 dosed orally for up to 14 days in adults previously treated for CDI; characterize the frequency and duration of stool colonization with VP 20621 strain of C.